We are analyzing https://link.springer.com/article/10.1007/s40257-023-00832-1.

Title:
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update | American Journal of Clinical Dermatology
Description:
Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

pubmed, article, bullous, google, scholar, pemphigoid, cas, patients, treatment, dermatol, ige, disease, central, omalizumab, study, therapy, cells, eosinophils, rituximab, dupilumab, case, levels, antibody, clinical, immunol, phase, antibp, skin, efficacy, autoantibodies, receptor, corticosteroids, activity, remission, eosinophil, weeks, monoclonal, severe, complement, psoriasis, role, nct, review, lesions, blister, diseases, clin, systemic, safety, igg,

Topics {✒️}

pre-plasma cell lineage t-/b-cell crosstalk anti-il-17a monoclonal antibody article download pdf anti-c5ar1 monoclonal antibody ige anti-bp180/bp230 antibodies antibody-secreting plasma cells enzyme-linked immunoassay index topical-steroid-resistant bullous pemphigoid frequently requires long-term th2 cell-induced cytokine cd20-positive plasma cells igg1-derived fc-fragment dipeptidyl-peptidase iv inhibitor b-cell depletion induces targeting eosinophil-related molecules pembrolizumab-induced bullous pemphigoid kilian eyerich declare th2-type inflammatory responses anti-bp180-nc16a ige [127] comprehensive pipeline update ige auto-antibodies correlates single-group trial testing double-blinded clinical trial gov/ct2/show/nct05061771 gov/ct2/show/nct04563923 gov/ct2/show/nct04465292 gov/ct2/show/nct04117932 gov/ct2/show/nct05267600 detected anti-bp230 ige high-dose systemic corticosteroids neutrophil-mediated autoimmune inflammation open-label clinical trial il-5ra alpha subunit humanized monoclonal antibody gov/ct2/show/nct04206553 gov/ct2/show/nct04612790 gov/ct2/show/nct04128176 cd20 monoclonal antibody ultra-low-dose rituximab b-cell proliferation population-based cohort study leukotriene b4 inhibitor stimulating leukotriene b4 corticosteroid-sparing adjuvant agents cd20 plasma cells mol biol cell depletes b-lymphocytes amber kt privacy choices/manage cookies

Questions {❓}

Can methotrexate be employed as monotherapy for bullous pemphigoid?
Gov/study/NCT03099538?
Gov/study/NCT04499235?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update
         description:Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.
         datePublished:2023-12-29T00:00:00Z
         dateModified:2023-12-29T00:00:00Z
         pageStart:195
         pageEnd:212
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s40257-023-00832-1
         keywords:
            Dermatology
            Pharmacotherapy
            Pharmacology/Toxicology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40257-023-00832-1/MediaObjects/40257_2023_832_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40257-023-00832-1/MediaObjects/40257_2023_832_Fig2_HTML.png
         isPartOf:
            name:American Journal of Clinical Dermatology
            issn:
               1179-1888
               1175-0561
            volumeNumber:25
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Meropi Karakioulaki
               affiliation:
                     name:University Hospital Freiburg
                     address:
                        name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kilian Eyerich
               affiliation:
                     name:University Hospital Freiburg
                     address:
                        name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Aikaterini Patsatsi
               affiliation:
                     name:Aristotle University
                     address:
                        name:Second Department of Dermatology, School of Medicine, Papageorgiou Hospital, Aristotle University, Thessaloníki, Greece
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update
      description:Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects. This review focuses on novel treatment options for BP, exploring therapies targeting different immune pathways. Rituximab, a CD20 monoclonal antibody, depletes B-lymphocytes and has shown efficacy in severe cases. Dupilumab, targeting interleukin (IL)-4 receptor α and thus blocking IL-4 and IL-13, downregulates type 2 helper (Th2) responses and has demonstrated promising results. Targeting eosinophil-related molecules using bertilimumab and AKST4290 has yielded positive results in clinical trials. Omalizumab, an immunoglobulin (Ig) E antibody, can reduce disease severity and allows corticosteroid tapering in a number of cases. Complement inhibitors such as nomacopan and avdoralimab are being investigated. IL-17 and IL-23 inhibitors such as secukinumab and tildrakizumab have shown potential in a limited number of case reports. Neonatal Fc receptor antagonists such as efgartigimod are under investigation. Additionally, topical therapies and Janus kinase inhibitors are being explored as potential treatments for BP. These novel therapies offer promising alternatives for managing BP, with potential to improve outcomes and reduce high cumulative doses of systemic corticosteroids and related toxicities. Further research, including controlled clinical trials, is needed to establish their efficacy, safety, and optimal dosing regimens for BP management.
      datePublished:2023-12-29T00:00:00Z
      dateModified:2023-12-29T00:00:00Z
      pageStart:195
      pageEnd:212
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s40257-023-00832-1
      keywords:
         Dermatology
         Pharmacotherapy
         Pharmacology/Toxicology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40257-023-00832-1/MediaObjects/40257_2023_832_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40257-023-00832-1/MediaObjects/40257_2023_832_Fig2_HTML.png
      isPartOf:
         name:American Journal of Clinical Dermatology
         issn:
            1179-1888
            1175-0561
         volumeNumber:25
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Meropi Karakioulaki
            affiliation:
                  name:University Hospital Freiburg
                  address:
                     name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kilian Eyerich
            affiliation:
                  name:University Hospital Freiburg
                  address:
                     name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Aikaterini Patsatsi
            affiliation:
                  name:Aristotle University
                  address:
                     name:Second Department of Dermatology, School of Medicine, Papageorgiou Hospital, Aristotle University, Thessaloníki, Greece
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:American Journal of Clinical Dermatology
      issn:
         1179-1888
         1175-0561
      volumeNumber:25
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Hospital Freiburg
      address:
         name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
         type:PostalAddress
      name:University Hospital Freiburg
      address:
         name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
         type:PostalAddress
      name:Aristotle University
      address:
         name:Second Department of Dermatology, School of Medicine, Papageorgiou Hospital, Aristotle University, Thessaloníki, Greece
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Meropi Karakioulaki
      affiliation:
            name:University Hospital Freiburg
            address:
               name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
               type:PostalAddress
            type:Organization
      name:Kilian Eyerich
      affiliation:
            name:University Hospital Freiburg
            address:
               name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
               type:PostalAddress
            type:Organization
      name:Aikaterini Patsatsi
      affiliation:
            name:Aristotle University
            address:
               name:Second Department of Dermatology, School of Medicine, Papageorgiou Hospital, Aristotle University, Thessaloníki, Greece
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
      name:Department of Dermatology and Venerology, Medical Center, University Hospital Freiburg, Freiburg, Germany
      name:Second Department of Dermatology, School of Medicine, Papageorgiou Hospital, Aristotle University, Thessaloníki, Greece

External Links {🔗}(544)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

4.87s.

LINK . SPRINGER . COM {}